Northrop Grumman’s Stock Lags Aerospace Peers Despite Strong Start to 2026

Northrop Grumman Corp. has recently underperformed broad aerospace and defense benchmarks, a gap highlighted by market comparisons published in early June. In the latest snapshot, the defense prime’s stock was down 7.7% year to date, compared with the iShares U.S. Aerospace & Defense ETF’s 4.8% gain over the same period.

Over the past three months, Northrop Grumman shares fell 30.7%, while the ETF declined 8.2%. The comparison also showed that Northrop Grumman had dipped 32% from its 52-week high of $774, reached March 3, another sign of relative weakness versus the broader group.

The market picture extends further back. Over the past 52 weeks, the stock was up 7.8%, lagging the ETF’s 25.4% uptick. Technical indicates in the same report suggested the shares have been trading below major moving averages, with the stock under its 200-day moving average since late April and below its 50-day moving average since mid-March.

Part of the debate is that the company has posted operating progress. On April 21, Northrop Grumman reported first-quarter 2026 financial results, including sales of $9.9 billion, up 4% year over year. Earnings per share (EPS), which measures profit attributable to each share, rose to $6.14, and the company said it reached agreements with the U.S. Air Force to increase B-21 production capacity and accelerate Sentinel initial operating capability.

In the same first-quarter release, Northrop Grumman also reported net awards of $9.8 billion and backlog of $95.6 billion. Backlog represents the value of work the company has already won but has not yet delivered, and it is often used by defense contractors as a proxy for future revenue visibility.

Still, the stock reaction was negative immediately after the earnings report. The market comparison said shares slipped nearly 7% during the trading session, with investors appearing to look past the beat as broader conditions weighed on the defense complex. In that context, the comparison noted that Northrop Grumman’s three-month performance was weaker than the ETF, even as it pointed to better-than-expected quarterly results.

Despite the recent drag, the report also found lingering analyst support. It cited a consensus rating of “Moderate Buy” from 23 analysts and a mean price target of $709.43, implying a 34.9% premium to the stock’s level at the time of publication. It also compared Northrop Grumman’s recent performance against TransDigm Group Inc. (TDG), noting TransDigm shares had declined over 52 weeks and year to date, while Northrop Grumman had fared better on those spans.

What remains unclear is how much of the underperformance is specific to Northrop Grumman versus sector-wide risk appetite, and what portion reflects expectations around program timing, margins, or cash flow rather than the quarterly results themselves. The publicly available comparison does not break down attribution in detail, and the company’s first-quarter release emphasizes bookings, backlog, and program ramps but does not directly explain why the stock fell despite reported EPS and sales growth.

Investors watching the next steps will likely focus on whether quarterly execution continues to translate into improving market confidence, particularly around large programs such as B-21 and Sentinel. Further market comparisons versus the ETF and peer moves may show whether the recent gap narrows, especially if additional order announcements and margin updates reinforce the company’s guidance posture for 2026.